Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11171MR)

This product GTTS-WQ11171MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11171MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15388MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ9855MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ14977MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ10962MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ12592MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ2824MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ7128MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ11315MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW